Regulative effects of ovarian steroids on rat gastric motility and sensitivity.
- Author:
Xia YANG
1
;
Ran LIU
;
Yan DONG
Author Information
1. Qilu Hospital, Shandong University, Jinan 250012, China. freetree1126@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
Animals;
Calcitonin Gene-Related Peptide;
blood;
Cholecystokinin;
blood;
Estradiol;
analogs & derivatives;
pharmacology;
physiology;
Female;
Gastric Emptying;
drug effects;
physiology;
Ovariectomy;
Progesterone;
pharmacology;
physiology;
Rats;
Rats, Sprague-Dawley;
Receptors, Calcitonin Gene-Related Peptide;
metabolism;
Receptors, Cholecystokinin;
metabolism;
Stomach;
metabolism;
physiology
- From:
Acta Physiologica Sinica
2006;58(3):275-280
- CountryChina
- Language:English
-
Abstract:
Women often complain gut symptoms during pregnancy and the luteal phase of the menstrual cycle. To investigate the relationship between ovarian steroids and the abnormal gut motility and sensitivity, the expressions of cholecystokinin (CCK), calcitonin gene-related peptide (CGRP) and their receptors in stomach were studied in ovariectomized rats. Blood samples were collected for estradiol (E(2)), progesterone (P(4)), CCK and CGRP radioimmunoassay. Expression of CCK(A) receptor in fundus was assessed by Western blot and CGRP receptor was determined by (125)I-CGRP radioligand binding assay (RBA). The replacement therapy with estradiol benzoate (EB) could dose-dependently increase the plasma CCK level and the expression of gastric CCK(A) receptor (P<0.05 respectively). P(4) replacement therapy could stimulate the release of CGRP and increase the binding sites of CGRP receptors in stomach (P<0.05 respectively). The combined effect of EB and P(4) was to stimulate the release of CCK and CGRP, and to increase the expressions of gastric CCK(A) and CGRP receptors. These results indicate that EB could inhibit gastric emptying by increasing CCK secretion and CCK(A) receptor expression in ovariectomized rats. P(4) could increase gut sensitivity by up-regulating the release of CGRP and the activity of CGRP receptor. It could be deduced from these observations that CCK(A) and CGRP receptor antagonists could be used for female patients who suffer from gastrointestinal dysfunction closely related with the menstrual cycle, such as distension, satiety, bloating and abdominal pain.
